Corazon Sanders
Director/Board Member at MOLECULAR TEMPLATES, INC.
Net worth: 2 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Oyler | M | 56 | 14 years | |
| Eric Poma | M | 52 | 24 years | |
| Jason Kim | M | 49 | 14 years | |
| Emil Kakkis | M | 63 | 14 years | |
| Fang Liang Zhang | M | 59 | 8 years | |
| Ying Huang | M | 51 | 5 years | |
| Patrick Yang | M | 75 |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.
AbGenomics International, Inc.
 AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | 3 years |
| Daniel Welch | M | 66 | 9 years | |
| Gabriela Gruia | M | 67 | 2 years | |
| Julia Wang | F | 53 | 4 years | |
| Lori Macomber | F | 53 | 5 years | |
| Judy Chou | M | 58 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| Leewen Lin | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Xiao Dong Wang | M | 61 | 14 years | |
| Deborah Dunsire | M | 61 | 7 years | |
| Anthony Hooper | M | 69 | 4 years | |
| Tomas Jan Heyman | M | 68 | 2 years | |
| Ye Wang | F | 55 | 9 years | |
| Eric Crombez | M | - | 7 years | |
| Qing Qing Yi | M | 52 | 10 years | |
| Wendy Yan | F | 58 | 10 years | |
| Xiao Hui Ji | M | 62 | 4 years | |
| Kristen Quigley | F | 53 | 7 years | |
| Wai Man Yau | M | 48 | 4 years | |
| Shehnaaz Suliman | M | 52 | 5 years | |
| Xiao Bin Wu | M | 62 | 6 years | |
| Lai Wang | M | 47 | 13 years | |
| Crystal Chen | F | - | 3 years | |
| Amrit Ray | M | 51 | 2 years | |
| Margaret Dugan | M | 67 | 2 years | |
| Li Mao | M | 67 | 2 years | |
| Patrick J. Casey | M | 68 | 4 years | |
| Ranjeev Krishana | M | 50 | 10 years | |
| Alessandro Riva | M | 63 | 2 years | |
| Harold Selick | M | 69 | 7 years | |
| Donald Glazer | M | 79 | 11 years | |
| Olivier Brandicourt | M | 68 | - | |
| Matthew Fust | M | 59 | 10 years | |
| Michael Goller | M | 49 | 9 years | |
| Scott Samuels | M | 54 | - | |
| Kevin Lalande | M | 51 | 15 years | |
| David Hoffmann | M | 79 | 7 years | |
| Shih-Yao Lin | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Ruth C. S. Li | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Michael Narachi | M | 64 | 9 years | |
| Eva Yin | F | - | - | |
| Yan Liu | M | - | 5 years | |
| Guowei Fang | M | - | 2 years | |
| Graham Hardiman | M | - | 3 years | |
| Liz Gosen | F | - | 5 years | |
| John C. Doyle | M | 55 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| Yuhong Qiu | M | - | 6 years | |
| Chan Lee | M | - | 2 years | |
| Stephen G. Juelsgaard | M | 75 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| Steven J. Gavel | M | - | 6 years | |
| Joshua Higa | M | - | - | |
| Tracy Luo | M | - | 6 years | |
| Ernie Meyer | M | 60 | 4 years | |
| John Pinion | M | 58 | 9 years | |
| Dennis Huang | M | 59 | 9 years | |
| Vimal Srivastava | M | 58 | 13 years | |
| Erik Harris | M | 54 | 7 years | |
| Sean Bohen | M | 58 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | 5 years |
| Yung-Hua Chung | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Hazel T. Y. Cheng | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Samuel Wadsworth | M | 75 | 7 years | |
| Theodore Huizenga | M | 53 | 10 years | |
| Be-Sheng Kuo | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Clare Fisher | F | 51 | 3 years | |
| Jason W. Radford | M | 42 | 4 years | |
| Karah Parschauer | F | 46 | 8 years | |
| Chia-Jung Yang | F | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Thomas Kassberg | M | 63 | 13 years | |
| Jessie Yeung | F | - | 5 years | |
| Guillaume Vignon | M | - | 6 years | |
| Liza Heapes | F | - | - | |
| Elaine Qian | F | - | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Adam Daniel Cutler | M | 50 | 4 years | |
| Robert Nelsen | M | 60 | 5 years | |
| Howard H. Pien | M | 66 | 4 years | |
| Maggie Wilderotter | F | 69 | 4 years | |
| Bill Aliski | M | 75 | 11 years | |
| Yong Ben | M | 50 | 3 years | |
| Jonathan Lanfear | M | 55 | 6 years | |
| Danielle Keatley | F | - | 5 years | |
| Scott Morenstein | M | 48 | 6 years | |
| Yung Cheng Chen | M | 67 | 6 years | |
| Thomas Daniel | M | 69 | 3 years | |
| Hal Barron | M | 62 | 4 years | |
| Lars Ekman | M | 74 | 7 years | |
| sam Su | M | 71 | 4 years | |
| Richard Klausner | M | 72 | 5 years | |
| David Hirsch | M | 53 | 6 years | |
| Thomas Malley | M | 55 | 8 years | |
| Anthony Evnin | M | 83 | 4 years | |
| Sean McLennan | M | 54 | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 69 | 71.88% |
| Cayman Islands | 27 | 28.13% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Corazon Sanders
- Personal Network
